Search Follow us

oncology venture

1 - 6 of 6
Sort by: popularity | newest
Page  of 1
Oncology Venture

Merger with Medical Prognosis Institute finalised

Update | Pharmaceutical & healthcare | 13 Sep 2018

In early September, Oncology Venture AB and Medical Prognosis Institute (MPI) completed their strategic merger and the new entity, Oncology Venture A/S (OV), now trades on the NASDAQ First North Stockholm. Recently, OV’s three highest priority programmes all demonstrated progress. OV reported interim data from the LiPlaCis trial and is increasing enrolment, whereas 2X-121 received an IND from the US FDA in ovarian cancer. Furthermore, OV has a 55% stake in dovitinib, a tyrosine kinase inhibitor that was in-licensed from Novartis.

Oncology Venture

PARP inhibitor Phase II study initiates

Update | Pharmaceutical & healthcare | 02 Jul 2018

Oncology Venture (OV) recently announced the initiation of its open-label Phase II study of 2X-121, a dual PARP-1/2 and TNKS-1/2 inhibitor, as a single agent in patients with metastatic breast cancer (mBC). The first patient, selected by OV’s 2X-121 drug response predictor (DRP) mRNA biomarker, was dosed in late June 2018. Also, OV announced that its impending merger with the Medical Prognosis Institute (MPI) will happen in September 2018. OV shareholders will own 51% of the new company.

Oncology Venture

Presence at ASCO 2018

Update | Pharmaceutical & healthcare | 11 Jun 2018

Oncology Venture (OV) attended the annual American Society of Clinical Oncology (ASCO) in June with three abstracts. Results from a Phase I study of 2X-121, a dual PARP-1/2 and TNKS-1/2 inhibitor, as a single agent in patients with solid tumours were presented along with data on the development of the 2X-121 drug response predictor (DRP) algorithm. OV also provided supplementary data supporting the LiPlaCis and APO010 programmes at the conference. In late May, OV announced the merger between OV and the Medical Prognosis Institute (MPI) was approved by the board of directors.

Oncology Venture

Optimising oncology drug development

Initiation | Pharmaceutical & healthcare | 04 May 2018

Oncology Venture (OV) is a cancer-focused pharmaceutical company that in-licenses discontinued oncology drugs at low cost and uses its mRNA-based drug response predictor (DRP) technology to identify and treat previously unidentified patient populations most likely to respond. OV conducts these focused Phase II trials with an aim to sell or out-license the Phase III-ready drugs with their respective DRPs. OV has in-licensed six assets to date, the most advanced of which is dovitinib from Novartis. Our initial valuation is SEK823.8m or SEK59.56 per share.

e-Therapeutics

Nearing prime time validation

Update | Pharmaceutical & healthcare | 05 Jan 2018

e-Therapeutics’ (ETX) Network-Driven Drug Discovery (NDD) platform has begun to deliver encouraging data that should support out-licensing of its immuno-oncology and hedgehog (Hh) projects with potential partners. Securing deals on the pipeline and the NDD platform are clear priorities for the company and having strong data in important new therapeutic areas will raise its profile. Although these are early-stage data, the company is moving in the right direction and meeting its targets. Our comparative venture capital (VC) methodology suggests an indicative value of GBP 41.9m.

Kazia Therapeutics

Yale JV to target ovarian cancer

QuickView | Pharmaceutical & healthcare | 12 Nov 2013

Novogen has taken an important step in the development of its super-benzopyran technology, with the formation of a joint venture with Yale University to develop a pipeline of compounds for ovarian cancer. The new venture, to be named CanTx, will initially screen Novogen's analogue library against Yale's ovarian cancer tissue bank. CanTx will fund further development of resulting compounds and, it is hoped, will ultimately become the vehicle to realise Novogen's vision of personalised chemotherapy. Meanwhile, Novogen continues its preclinical work aimed at bring the Trilexium lead candidate to the IND stage by Q314.